Gesellschaftsrecht / M&A

Kapitalmarkt

Finanzmarktrecht

Steuern

Homburger News

Share-Image Teamplate Deals-and-Cases

On March 10, 2025, Sunshine SwissCo GmbH (a consortium led by EQT), the Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte. Ltd. (all acting as the Sellers) announced the launch of an accelerated bookbuilding process to professional investors in Switzerland and to qualified investors outside Switzerland, which led to the successful placement of 15,000,000 shares in Galderma Group AG (Galderma) at a price of CHF 89 per share (the Placement), raising a total of ca. CHF 1.335 bn in total.
The Sellers will remain shareholders of 48.18% of the share capital of Galderma. EQT’s representation on the Board of Directors of Galderma remains unchanged as a result of the Placement. Such Placement will broaden Galderma&#8217;s shareholder base and free float. In connection therewith, the Sellers have agreed to a 90-day lock-up period, subject to certain customary exceptions, with respect to their remaining holding in Galderma.
The Placement settled on March 13, 2025. Following the Placement, no changes to the Galderma board of directors and its governance are envisioned.
Homburger acted as transaction counsel to EQT.
The Homburger team was led by Frank Gerhard (Corporate / M&amp;A, Capital Markets) and included Margrit Marti, Estelle Piccard, Héloïse de Jamblinne and Lucas Forrer (all Corporate / M&amp;A, Capital Markets), Micha Fankhauser (Financial Market Regulation) as well as Stefan Oesterhelt (Tax).

Homburger advises EQT on the sale of 6.3% of Galderma's share capital via an accelerated bookbuilding process

IP / IT

Windward Bio_we_640x140

Homburger and Windward Bio

On January 10, 2025, Windward Bio Group AG, a Swiss-based private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, announced its launch with a USD 200 m series A financing from lead investors OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities, and co-investors SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital and Pivotal bioVenture Partners. Windward Bio has entered into an agreement to license WIN378, a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal lymphopoietin (TSLP), from Kelun-Biotech and Harbour BioMed for global rights, excepting China and select smaller markets in Asia.
Proceeds from the financing will be used to develop a phase 2-ready, long-acting anti-TSLP antibody with best-in-class potential in asthma and chronic obstructive pulmonary disease (COPD).
Homburger AG advises Windward Bio on its set-up and financing. The Homburger team comprises Andreas Müller, Margrit Marti, Oliver Kneubühl, Kaiyan Yeo, Eric Huber, Jonas Stähli, Rebecca Sigrist and Carolina Rodriguez (all Corporate / M&amp;A), Stefan Oesterhelt and Juliette Buob (both Tax) and Luca Dal Molin (IP / IT).

Homburger advises Windward Bio on its USD 200 m Series A Financing

Wettbewerb

20240706_EQT-Galderma

On August 5, 2024, L&#8217;Oréal and Galderma announced the acquisition of a 10% stake in Galderma Group AG from Sunshine SwissCo AG (a consortium led by EQT), Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte. Ltd. (all acting as sellers), for a non-disclosed amount. In connection therewith, L&#8217;Oréal has agreed vis-à-vis Sunshine SwissCo AG to certain undertakings as part of a shareholders&#8216; agreement. Following the transaction, no changes to the Galderma board of directors and its governance are envisioned.
In addition, L&#8217;Oréal and Galderma have agreed to work towards a strategic scientific partnership that will leverage the undisputed expertise of both companies: Galderma&#8217;s across a broad range of dermatological solutions, and L&#8217;Oréal’s expertise in skin biology, diagnostic tools and evaluation methods.
Homburger acted as transaction counsel to EQT. The team was led by Frank Gerhard and Margrit Marti (both Corporate / M&amp;A, Capital Markets) and comprises Estelle Piccard, Simone Schmid and Héloïse de Jamblinne (all Corporate / M&amp;A), Stefan Oesterhelt (Tax), Richard Stäuber (Competition) as well as Micha Fankhauser (Financial Market Regulation).

Margrit
Marti

Homburger advises EQT on the sale of 6.3% of Galderma's share capital via an accelerated bookbuilding process

Homburger advises Windward Bio on its USD 200 m Series A Financing

Homburger advises EQT on its sale of 10% in Galderma to L'Oréal

Private Equity 2024: Switzerland

Nutzbarmachung des neuen Aktienrechts für Private Equity und Venture Capital

Swiss Corporation Law: A Primer for Legal Practitioners

Join the Team

Margrit Marti

Karriere

Sprachen

Zulassung

Teams

MargritMarti

Homburger advises EQT on the sale of 6.3% of Galderma's share capital via an accelerated bookbuilding process

Homburger advises Windward Bio on its USD 200 m Series A Financing

Homburger advises EQT on its sale of 10% in Galderma to L'Oréal

Private Equity 2024: Switzerland

Nutzbarmachung des neuen Aktienrechts für Private Equity und Venture Capital

Swiss Corporation Law: A Primer for Legal Practitioners

Join the Team

Margrit Marti

Karriere

Sprachen

Zulassung

Teams

Margrit
Marti